MRSA Identification via MALDI-TOF Mass Signal Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying methicillin-resistant Staphylococcus aureus (MRSA) are slow, costly, and require high operator training, with existing biomarkers showing inconsistent results with clinical tests, necessitating the need for more accurate and rapid diagnostic tools.
Innovation Solution
A method using MALDI-TOF MS to identify MRSA by detecting a specific mass signal at m/z 6580-6600, which corresponds to a peptide biomarker, allowing for rapid and accurate differentiation from methicillin-sensitive Staphylococcus aureus (MSSA) through the analysis of mass spectra and machine learning algorithms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional microbial culture and biochemical identification methods are used, then reliable bacterial identification can be achieved, but the diagnostic time is excessively long (3-5 days)
Solution Approach 1:
The invention extracts and identifies specific protein markers (alpha-hemolysin and PVL toxins) that are characteristic of MRSA from the complex bacterial culture. By focusing on these specific extracted markers rather than performing complete biochemical identification, the method achieves rapid MRSA detection within hours while maintaining high accuracy, resolving the contradiction between reliability and time consumption.
2Measurement precision
If complete microbial culture identification and antibiotic susceptibility testing are performed, then accurate pathogen diagnosis and antibiotic resistance determination can be achieved, but the treatment time is delayed
Solution Approach 1:
The invention performs preliminary identification of MRSA-specific protein markers (alpha-hemolysin and PVL toxins) before complete antibiotic susceptibility testing is finished. By detecting these specific markers early in the process, clinicians can initiate appropriate antibiotic treatment sooner while the comprehensive susceptibility testing continues in parallel, thereby reducing treatment delay without sacrificing diagnostic accuracy.
3Productivity
If empirical antibiotic therapy is started immediately, then treatment can begin without delay, but antibiotic misuse and resistance development may occur
Solution Approach 1:
The invention provides rapid feedback by detecting MRSA-specific protein markers within hours of sample collection. This early feedback enables clinicians to adjust antibiotic therapy appropriately - switching from empirical broad-spectrum antibiotics to targeted anti-MRSA antibiotics - thereby preventing antibiotic misuse and resistance development while maintaining rapid treatment initiation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the time and cost of MRSA identification, providing a clinically accurate and rapid judgment standard for antibiotic treatment by utilizing a peptide biomarker detectable through MALDI-TOF MS, improving patient outcomes and reducing antibiotic misuse.
Implementation Method 1
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
Implementation Method 2
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
Data Source
AI summary
Disclosed is a method for identifying methicillin-resistant Staphylococcus aureus through detection a mass signal at m/z of 6580-6600 in the MALDI-TOF mass spectrum. Also disclosed is a novel peptide biomarker, which consists of SEQ NO ID:5 and the use thereof for detection and/or identification of methicillin-resistant Staphylococcus aureus.